This article is more than 5 years old. Information may no longer be current.

Regeneron reports 21% rise in total revenues for second quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Total revenues for Regeneron increased by 21% to $1.213 billion in the second quarter, up from $999 million in the second quarter of 2015, according to a press release.

U.S. net sales of Eylea (aflibercept) increased 27% to $831 million, up from $655 million in the second quarter of 2015, while global net sales of Eylea increased 33% to $1.32 billion compared with the same period a year earlier.

Combined net product sales totaled $834 million, up from $658 million in the second quarter of 2015.

GAAP net income totaled $196 million, or $1.88 per basic share and $1.69 per diluted share. In the second quarter of 2015, GAAP net income was $195 million, or $1.89 per basic share and $1.69 per diluted share.

Research and development expenses totaled $560 million, up from $390 million in the second quarter of 2015.